Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Renatus

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Medicinal Chemistry|November 20, 2020
Optimization of the <i>In Vivo</i> Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole BloodJean Quancard, Oliver Simic, Carole Pissot Soldermann, et al.
Nature Chemical Biology|January 30, 2019
An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patientJean Quancard, Theo Klein, Shan-Yu Fung, et al.
Immunology and Cell Biology|January 24, 2018
The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibitionMaureen Bardet, Adeline Unterreiner, Claire Malinverni, et al.
Journal of Medicinal Chemistry|November 30, 2020
Discovery of Potent, Highly Selective, and <i>In Vivo</i> Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold MorphingCarole Pissot Soldermann, Oliver Simic, Martin Renatus, et al.
Molecular Cell|June 30, 2019
Structural Basis of BRCC36 Function in DNA Repair and Immune RegulationJulius Rabl, Richard D Bunker, Andreas D Schenk, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 LigaseKlemens Hoegenauer, Shaojian An, Jake Axford, et al.
Nature Communications|December 9, 2025
Fragment-based discovery enables direct targeting of the melanoma oncogene MITFDeborah Castelletti, Jürgen Hinrichs, Goran Malojčić, et al.
Nature Communications|August 19, 2024
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistanceMartin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Nature Communications|January 4, 2024
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistanceMartin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Journal of Medicinal Chemistry|June 20, 2020
Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family ApproachEdwige Lorthiois, James Roache, David Barnes-Seeman, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Medicinal Chemistry|November 20, 2020
Optimization of the <i>In Vivo</i> Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole BloodJean Quancard, Oliver Simic, Carole Pissot Soldermann, et al.
Nature Chemical Biology|January 30, 2019
An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patientJean Quancard, Theo Klein, Shan-Yu Fung, et al.
Immunology and Cell Biology|January 24, 2018
The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibitionMaureen Bardet, Adeline Unterreiner, Claire Malinverni, et al.
Journal of Medicinal Chemistry|November 30, 2020
Discovery of Potent, Highly Selective, and <i>In Vivo</i> Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold MorphingCarole Pissot Soldermann, Oliver Simic, Martin Renatus, et al.
Molecular Cell|June 30, 2019
Structural Basis of BRCC36 Function in DNA Repair and Immune RegulationJulius Rabl, Richard D Bunker, Andreas D Schenk, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 LigaseKlemens Hoegenauer, Shaojian An, Jake Axford, et al.
Nature Communications|December 9, 2025
Fragment-based discovery enables direct targeting of the melanoma oncogene MITFDeborah Castelletti, Jürgen Hinrichs, Goran Malojčić, et al.
Nature Communications|August 19, 2024
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistanceMartin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Nature Communications|January 4, 2024
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistanceMartin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Journal of Medicinal Chemistry|June 20, 2020
Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family ApproachEdwige Lorthiois, James Roache, David Barnes-Seeman, et al.
Pageof 3